Karin Vanderkerken

Best Publications

• Bone marrow stromal cell-derived exosomes as communicators in drug resistance in multiple myeloma cells.

  Jinheng Wang;Jinheng Wang;An Hendrix;Sophie Hernot;Miguel Lemaire

  476
  Citations

• Zoledronic Acid Treatment of 5T2MM‐Bearing Mice Inhibits the Development of Myeloma Bone Disease: Evidence for Decreased Osteolysis, Tumor Burden and Angiogenesis, and Increased Survival

  Peter I Croucher;Hendrik De Raeve;Mark J Perry;Anja Hijzen

  393
  Citations

• Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche.

  Michelle A Lawson;Michelle M McDonald;Michelle M McDonald;Natasa Kovacic;Weng Hua Khoo;Weng Hua Khoo

  383
  Citations

• Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features

  Abdel Kareem Azab;Jinsong Hu;Phong Quang;Feda Azab

  354
  Citations

• Cell biology of liver endothelial and Kupffer cells.

  B Smedsrød;P J De Bleser;F Braet;P Lovisetti

  298
  Citations

• Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma.

  Deborah J Heath;Andrew D Chantry;Clive H Buckle;Les Coulton

  294
  Citations

• Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma.

  Karin Vanderkerken;Evy De Leenheer;Claire Shipman;Kewal Asosingh

  236
  Citations

• Liver cell heterogeneity: functions of non-parenchymal cells.

  Unknown

  192
  Citations

• Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug.

  Jinsong Hu;Jinsong Hu;Damian R Handisides;Els Van Valckenborgh;Hendrik De Raeve

  184
  Citations

• Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma.

  Michelle M. McDonald;Michelle M. McDonald;Michaela R. Reagan;Michaela R. Reagan;Scott E. Youlten;Scott E. Youlten;Sindhu T. Mohanty

  184
  Citations

• Neighboring adipocytes participate in the bone marrow microenvironment of multiple myeloma cells.

  J. Caers;S. Deleu;Z. Belaid;H. De Raeve

  183
  Citations

• Organ involvement and phenotypic adhesion profile of 5T2 and 5T33 myeloma cells in the C57BL/KaLwRij mouse

  K. Vanderkerken;H. De Raeve;E. Goes;S. Van Meirvenne

  174
  Citations

• In anemia of multiple myeloma, hepcidin is induced by increased bone morphogenetic protein 2

  Ken Maes;Elizabeta Nemeth;G. David Roodman;Alissa Huston

  173
  Citations

• Multiple myeloma biology: lessons from the 5TMM models.

  Karin Vanderkerken;Kewal Asosingh;Peter Croucher;Ben Van Camp

  169
  Citations

• Inhibiting the IGF-1 receptor tyrosine kinase with the cyclolignan PPP: an in vitro and in vivo study in the 5T33MM mouse model

  Eline Menu;Helena Jernberg-Wiklund;Thomas Stromberg;Hendrik De Raeve

  168
  Citations

• Chemokine receptor CCR2 is expressed by human multiple myeloma cells and mediates migration to bone marrow stromal cell-produced monocyte chemotactic proteins MCP-1, -2 and -3

  I Vande Broek;K Asosingh;K Vanderkerken;N Straetmans

  166
  Citations

• The bone marrow microenvironment enhances multiple myeloma progression by exosome-mediated activation of myeloid-derived suppressor cells.

  Jinheng Wang;Kim De Veirman;Nathan De Beule;Ken Maes

  163
  Citations

• Inhibiting activin-A signaling stimulates bone formation and prevents cancer-induced bone destruction in vivo.

  Andrew D Chantry;Debby Heath;Aaron W Mulivor;Scott Pearsall

  159
  Citations

• A novel therapeutic combination using PD 0332991 and bortezomib: study in the 5T33MM myeloma model.

  Eline Menu;Josefina Garcia;Xiangao Huang;Maurizio Di Liberto

  158
  Citations

• Exosomes play a role in multiple myeloma bone disease and tumor development by targeting osteoclasts and osteoblasts.

  Sylvia Faict;Joséphine Muller;Kim De Veirman;Elke De Bruyne

  152
  Citations